Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
Alimentary Pharmacology & Therapeutics|June 6, 2019
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort studyAurelien Amiot, Melanie Serrero, Laurent Peyrin-Biroulet, et al.Alimentary Pharmacology & Therapeutics|April 5, 2021
Determinants of IBD-related disability: a cross-sectional survey from the GETAIDJenny Tannoury, Maria Nachury, Carole Martins, et al.Journal of Crohn'S & Colitis|May 7, 2019
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort StudyBenedicte Caron, Laurent Peyrin-Biroulet, Benjamin Pariente, et al.Gut|January 26, 2017
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) studyYoram Bouhnik, Franck Carbonnel, David Laharie, et al.Alimentary Pharmacology & Therapeutics|December 19, 2022
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort studyMathurin Fumery, Antoine Defrance, Xavier Roblin, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 28, 2023
Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAIDRose Al Bacha, Yoram Bouhnik, Melanie Serrero, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 27, 2016
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseAurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, et al.Journal of Crohn'S & Colitis|September 10, 2025
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAIDPauline Wils, Romain Altwegg, Anthony Buisson, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 16, 2022
Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAIDAurelien Amiot, Philippe Seksik, Jean-Marie Reimund, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID StudyMathurin Fumery, Benedicte Caron, Xavier Hébuterne, et al.Pageof 6